Grouping mutations based on their likelihood of response to specific drug types in future EGFR TKI trials may eventually help physicians tailor treatments for patients with atypical mutations. Read more
Investigators at Sarah Cannon look to next-generation sequencing for molecular signatures that may correlate with response. Read more
Researchers say increased screening of at-risk populations, including those who have never smoked, may improve survival more than any other strategy. Read more
Study provides evidence to support the potential role of real-world data in consideration of technologies where only single-arm trial data exists. Read more
When publicly reported patient outcomes emerge, the data available to patients should paint the most complete picture possible. Read more
Combining fixed- and weight-based dosing approaches may reduce costs without compromising efficacy. Read more
During the 2022 European Lung Cancer Congress, experts reviewed evidence on drugs targeting MET exon 14 skipping mutations and RET, HER2, and BRAF alterations. Read more
A presentation at the 2022 European Lung Cancer Congress convinced attendees that the current system for staging lung cancer needs refinement. Read more
A real-world look at diagnostic-therapeutic pathways explores how they may help provide optimal, innovative care without ballooning costs. Read more
In the search to understand the mechanisms of metastasis, researchers have expanded the spectrum of SCLC clinical specimens amenable for single-cell resolution analysis. Read more